(+) -Rocaglamide

(+) -Rocaglamide is the dextrorotatory enantiomer of Rocaglamide (HY-19356) . Rocaglamide (Roc-A) is isolated from the genus Aglaia and can be used for coughs, injuries, asthma and inflammatory skin diseases. Rocaglamide is a potent inhibitor of NF-κB activation in T-cells. Rocaglamide is a potent and selective heat shock factor 1 (HSF1) activation inhibitor with an IC50 of 50 nM. Rocaglamide inhibits the function of the translation initiation factor eIF4A. Rocaglamide also has anticancer properties in leukemia[1][2][3].

Product Specifications

CAS Number

[1699754-37-4]

Target

Drug Derivative; Eukaryotic Initiation Factor (eIF) ; HSP; NF-κB

Related Pathways

Cell Cycle/DNA Damage; Metabolic Enzyme/Protease; NF-κB; Others

Field of Research

Cancer; Inflammation/Immunology

Smiles

O[C@@]12[C@@](OC3=CC(OC)=CC(OC)=C32)(C4=CC=C(C=C4)OC)[C@@H](C5=CC=CC=C5)[C@@H]([C@@H]1O)C(N(C)C)=O

Molecular Formula

C29H31NO7

Molecular Weight

505.56

References & Citations

[1]Santagata S, et al. Tight coordination of protein translation and heat shock factor 1 activation supports the anabolic malignant state. Science. 2013 Jul 19; 341 (6143) : 1238303.|[2]Luan Z, et al. Rocaglamide overcomes tumor necrosis factor-related apoptosis-inducing ligand resistance in hepatocellular carcinoma cells by attenuating the inhibition of caspase-8 through cellular FLICE-like-inhibitory protein downregulation. Mol Med Rep|[3]Baumann B, et al. Rocaglamide derivatives are potent inhibitors of NF-kappa B activation in T-cells. J Biol Chem. 2002 Nov 22;277 (47) :44791-800.